{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:00:53Z","timestamp":1789563653351,"version":"build-2803163510"},"reference-count":202,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-10-IDEX-0002"],"award-info":[{"award-number":["ANR-10-IDEX-0002"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-17-EURE-0023"],"award-info":[{"award-number":["ANR-17-EURE-0023"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-20-SFRI-0012"],"award-info":[{"award-number":["ANR-20-SFRI-0012"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-10-INBS-05"],"award-info":[{"award-number":["ANR-10-INBS-05"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-24-CE44-1817"],"award-info":[{"award-number":["ANR-24-CE44-1817"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003768","name":"Universit\u00e9 de Strasbourg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003768","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Biology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jmb.2025.169384","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T23:14:22Z","timestamp":1754954062000},"page":"169384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["DNA Topoisomerase II Mutations in Cancer: Structural Impact and Drug Response in High-grade Serous Ovarian Carcinoma"],"prefix":"10.1016","volume":"438","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2067-3758","authenticated-orcid":false,"given":"Viola","family":"Mazzoleni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Boichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7793-4029","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Lamour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmb.2025.169384_b0005","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1073\/pnas.84.20.7024","article-title":"Supercoiling of the DNA template during transcription","volume":"84","author":"Liu","year":"1987","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169384_b0010","doi-asserted-by":"crossref","DOI":"10.1007\/s13277-015-4270-9","article-title":"Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy","author":"Ali","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.jmb.2025.169384_b0015","doi-asserted-by":"crossref","DOI":"10.1038\/nrm3228","article-title":"All tangled up: how cells direct, manage and exploit topoisomerase function","author":"Vos","year":"2011","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2025.169384_b0020","doi-asserted-by":"crossref","first-page":"7876","DOI":"10.1073\/pnas.95.14.7876","article-title":"Structural similarities between topoisomerases that cleave one or both DNA strands","volume":"95","author":"Berger","year":"1998","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169384_b0025","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1038\/onc.2014.332","article-title":"Topoisomerase II\u03b1 in chromosome instability and personalized cancer therapy","volume":"34","author":"Chen","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.jmb.2025.169384_b0030","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41580-022-00452-3","article-title":"Human topoisomerases and their roles in genome stability and organization","volume":"23","author":"Pommier","year":"2022","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2025.169384_b0035","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1038\/s41598-025-85929-9","article-title":"Multi-omics analysis reveals the panoramic picture of TOP2A in pan-cancer","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jmb.2025.169384_b0040","doi-asserted-by":"crossref","first-page":"11161","DOI":"10.1038\/s41598-022-15205-7","article-title":"Oncogenic role and potential regulatory mechanism of topoisomerase II\u03b1 in a pan-cancer analysis","volume":"12","author":"Wang","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jmb.2025.169384_b0045","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2001760117","article-title":"Topoisomerase IIa is essential for maintenance of mitotic chromosome structure","author":"Nielsen","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169384_b0050","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169384_b0055","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/bjc.1997.227","article-title":"The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues","volume":"75","author":"Turley","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jmb.2025.169384_b0060","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1006\/excr.1994.1046","article-title":"Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions","volume":"210","author":"Zini","year":"1994","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jmb.2025.169384_b0065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s10020-022-00592-4","article-title":"TOP2A deficiency leads to human recurrent spontaneous abortion and growth retardation of mouse pre-implantation embryos","volume":"28","author":"Duan","year":"2022","journal-title":"Mol. Med. Camb. Mass"},{"issue":"210","key":"10.1016\/j.jmb.2025.169384_b0070","first-page":"126","article-title":"Topoisomerases in the immune cell development and function","volume":"1950","author":"Muralidhara","year":"2023","journal-title":"J. Immunol. (Baltimore, Md)"},{"key":"10.1016\/j.jmb.2025.169384_b0075","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12958-022-01013-1","article-title":"TOP2A deficit-induced abnormal decidualization leads to recurrent implantation failure via the NF-\u03baB signaling pathway","volume":"20","author":"Fu","year":"2022","journal-title":"Reprod. Biol. Endocrinol."},{"key":"10.1016\/j.jmb.2025.169384_b0080","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.3390\/ijms19092765","article-title":"TOP2B: the first thirty years","volume":"19","author":"Austin","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jmb.2025.169384_b0085","doi-asserted-by":"crossref","first-page":"E934","DOI":"10.1073\/pnas.1119798109","article-title":"Target genes of topoisomerase II\u03b2 regulate neuronal survival and are defined by their chromatin state","volume":"109","author":"Tiwari","year":"2012","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169384_b0090","doi-asserted-by":"crossref","DOI":"10.1126\/science.287.5450.131","article-title":"DNA topoisomerase II\u03b2 and neural development","author":"Yang","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169384_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.982870","article-title":"Topoisomerase 2\u03b2 and DNA topology during B cell development","volume":"13","author":"Papapietro","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jmb.2025.169384_b0100","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1038\/s41467-019-11570-6","article-title":"Mutations in topoisomerase II\u03b2 result in a B cell immunodeficiency","volume":"10","author":"Broderick","year":"2019","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2025.169384_b0105","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0378-1119(98)00468-5","article-title":"Structural organization of the human TOP2A and TOP2B genes","volume":"221","author":"Lang","year":"1998","journal-title":"Gene"},{"key":"10.1016\/j.jmb.2025.169384_b0110","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1093\/nar\/21.16.3719","article-title":"Human cells express two differentially spliced forms of topoisomerase II beta mRNA","volume":"21","author":"Davies","year":"1993","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169384_b0115","doi-asserted-by":"crossref","first-page":"D609","DOI":"10.1093\/nar\/gkae1010","article-title":"UniProt: the Universal Protein Knowledgebase in 2025","volume":"53","author":"The UniProt Consortium","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169384_b0120","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1083\/jcb.136.4.775","article-title":"Cell cycle\u2013coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities","volume":"136","author":"Meyer","year":"1997","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jmb.2025.169384_b0125","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1593\/neo.04394","article-title":"pRb-independent growth arrest and transcriptional regulation of E2F target genes","volume":"7","author":"McCabe","year":"2005","journal-title":"Neoplasia N.Y.N."},{"key":"10.1016\/j.jmb.2025.169384_b0130","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/cncr.10450","article-title":"Topoisomerase II\u03b1 gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients","volume":"94","author":"Liu","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.jmb.2025.169384_b0135","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1093\/nar\/24.22.4464","article-title":"p53 regulates the minimal promoter of the human topoisomerase II gene","volume":"24","author":"Sandri","year":"1996","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169384_b0140","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1128\/MCB.17.1.389","article-title":"Inhibition of DNA topoisomerase II\u03b1 gene expression by the p53 tumor suppressor","volume":"17","author":"Wang","year":"1997","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2025.169384_b0145","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2199-8-36","article-title":"Down-regulation of human topoisomerase II\u03b1 expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions","volume":"8","author":"Williams","year":"2007","journal-title":"BMC Mol. Biol."},{"key":"10.1016\/j.jmb.2025.169384_b0150","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.3390\/cancers14143516","article-title":"MicroRNAs, tristetraprolin family members and HuR: a complex interplay controlling cancer-related processes","volume":"14","author":"Sobolewski","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jmb.2025.169384_b0155","doi-asserted-by":"crossref","first-page":"589","DOI":"10.7150\/jca.64017","article-title":"TOP2A promotes proliferation and metastasis of hepatocellular carcinoma regulated by miR-144-3p","volume":"13","author":"Wang","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.jmb.2025.169384_b0160","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature11083","article-title":"A unifying model for mTORC1-mediated regulation of mRNA translation","volume":"485","author":"Thoreen","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169384_b0165","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cell.2005.10.024","article-title":"mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events","volume":"123","author":"Holz","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2025.169384_b0170","doi-asserted-by":"crossref","first-page":"9272","DOI":"10.1038\/s41598-018-27606-8","article-title":"Post-translational modifications in DNA topoisomerase 2\u03b1 highlight the role of a eukaryote-specific residue in the ATPase domain","volume":"8","author":"Bedez","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jmb.2025.169384_b0175","doi-asserted-by":"crossref","first-page":"25892","DOI":"10.1021\/acsomega.1c02083","article-title":"Exploration of the role of the C-terminal domain of human DNA topoisomerase II\u03b1 in catalytic activity","volume":"6","author":"Dougherty","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.jmb.2025.169384_b0180","first-page":"149","article-title":"The interplay between DNA topoisomerase 2a post-translational modifications and drug resistance","volume":"3","author":"Lotz","year":"2020","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.jmb.2025.169384_b0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cell.2008.01.045","article-title":"Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha","volume":"133","author":"Dawlaty","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2025.169384_b0190","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.celrep.2014.01.017","article-title":"A synthetic lethal interaction between APC\/C and topoisomerase poisons uncovered by proteomic screens","volume":"6","author":"Eguren","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.jmb.2025.169384_b0195","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/jnr.23403","article-title":"Specificity protein 1 regulates topoisomerase II\u03b2 expression in SH-SY5Y cells during neuronal differentiation","volume":"92","author":"Guo","year":"2014","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jmb.2025.169384_b0200","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1042\/bj20020791","article-title":"Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites","volume":"368","author":"Lok","year":"2002","journal-title":"Biochem. J."},{"key":"10.1016\/j.jmb.2025.169384_b0205","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3390\/genes10110859","article-title":"Cell cycle-dependent control and roles of DNA topoisomerase II","volume":"10","author":"Lee","year":"2019","journal-title":"Genes"},{"key":"10.1016\/j.jmb.2025.169384_b0210","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q","article-title":"Eukaryotic DNA topoisomerase II beta","volume":"20","author":"Austin","year":"1998","journal-title":"BioEssays News Rev. Mol. Cell. Dev. Biol."},{"key":"10.1016\/j.jmb.2025.169384_b0215","doi-asserted-by":"crossref","first-page":"8341","DOI":"10.1038\/s41467-023-44089-y","article-title":"ERK2-topoisomerase II regulatory axis is important for gene activation in immediate early genes","volume":"14","author":"Bunch","year":"2023","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2025.169384_b0220","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.613","article-title":"Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements","volume":"42","author":"Haffner","year":"2010","journal-title":"Nature Genet."},{"key":"10.1016\/j.jmb.2025.169384_b0225","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1126\/science.1127196","article-title":"A topoisomerase II\u00df-mediated dsDNA break required for regulated transcription","volume":"312","author":"Ju","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169384_b0230","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1128\/MCB.01576-07","article-title":"Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance","volume":"28","author":"McNamara","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2025.169384_b0235","doi-asserted-by":"crossref","first-page":"14806","DOI":"10.3390\/ijms241914806","article-title":"To break or not to break: the role of TOP2B in transcription","volume":"24","author":"Cowell","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jmb.2025.169384_b0240","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1038\/ncomms3478","article-title":"Gene regulation and priming by topoisomerase II\u03b1 in embryonic stem cells","volume":"4","author":"Thakurela","year":"2013","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2025.169384_b0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274546","article-title":"An integrated multi-omics analysis of topoisomerase family in pan-cancer: friend or foe?","volume":"17","author":"Zhou","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jmb.2025.169384_b0250","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add4920","article-title":"Untangling the roles of TOP2A and TOP2B in transcription and cancer","volume":"8","author":"Uusk\u00fcla-Reimand","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jmb.2025.169384_b0255","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cancergen.2024.10.005","article-title":"Elucidating the prognostic and therapeutic significance of TOP2A in various malignancies","volume":"288\u2013289","author":"Liu","year":"2024","journal-title":"Cancer Genet."},{"key":"10.1016\/j.jmb.2025.169384_b0260","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/1097-0215(20001001)88:1<99::AID-IJC16>3.0.CO;2-4","article-title":"Ectopic expression of human topoisomerase II\u03b1 fragments and etoposide resistance in mammalian cells","volume":"88","author":"Ernst","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jmb.2025.169384_b0265","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/modpathol.2009.14","article-title":"Topoisomerase II\u03b1 mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis","volume":"22","author":"Faggad","year":"2009","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.jmb.2025.169384_b0270","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10549-012-2167-5","article-title":"TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy","volume":"135","author":"Wang","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jmb.2025.169384_b0275","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ygyno.2015.06.025","article-title":"TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer","volume":"138","author":"Erriquez","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jmb.2025.169384_b0280","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s12672-024-01295-4","article-title":"Expression and biological significance of topoisomerase II \u03b1 (TOP2A) in oral squamous cell carcinoma","volume":"15","author":"Cheng","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.jmb.2025.169384_b0285","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.canlet.2008.11.018","article-title":"Increased topoisomerase II\u03b1 expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis","volume":"276","author":"Coss","year":"2009","journal-title":"Cancer Letters"},{"key":"10.1016\/j.jmb.2025.169384_b0290","doi-asserted-by":"crossref","first-page":"10906","DOI":"10.1038\/s41598-023-38117-6","article-title":"The role of TOP2A in immunotherapy and vasculogenic mimicry in non-small cell lung cancer and its potential mechanism","volume":"13","author":"Wu","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jmb.2025.169384_b0295","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12935-021-02439-0","article-title":"Study on the expression of TOP2A in hepatocellular carcinoma and its relationship with patient prognosis","volume":"22","author":"Meng","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.jmb.2025.169384_b0300","first-page":"1","article-title":"Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention","volume":"7","author":"Lee","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.jmb.2025.169384_b0305","article-title":"Targeting TOP2B as a vulnerability in aging and aging-related diseases","volume":"1870","author":"Zhu","year":"2024","journal-title":"Biochim. Biophys. Acta BBA \u2013 Mol. Basis Dis."},{"key":"10.1016\/j.jmb.2025.169384_b0310","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.1158\/1078-0432.CCR-21-0312","article-title":"TOP2B enzymatic activity on promoters and introns modulates multiple oncogenes in human gliomas","volume":"27","author":"Gonzalez-Buendia","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.jmb.2025.169384_b0315","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.261931","article-title":"DNA-PKcs-mediated transcriptional regulation of TOP2B drives chemoresistance in acute myeloid leukemia","volume":"137","author":"Mishra","year":"2024","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.jmb.2025.169384_b0320","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1242\/bio.014308","article-title":"Genome-wide ChIP-seq analysis of human TOP2B occupancy in MCF7 breast cancer epithelial cells","volume":"4","author":"Manville","year":"2015","journal-title":"Biol. Open"},{"key":"10.1016\/j.jmb.2025.169384_b0325","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12935-016-0339-9","article-title":"Topoisomerase II\u03b2 mediates the resistance of glioblastoma stem cells to replication stress-inducing drugs","volume":"16","author":"Kenig","year":"2016","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.jmb.2025.169384_b0330","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1038\/s41598-025-86865-4","article-title":"Identification of a novel TOP2B::AFF2 fusion gene in B-cell acute lymphoblastic leukemia","volume":"15","author":"Liu","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jmb.2025.169384_b0335","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/annonc\/mdv164","article-title":"Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study","volume":"26","author":"Beltrame","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jmb.2025.169384_b0340","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/bjc.2012.206","article-title":"High TOP2B\/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia","volume":"107","author":"Song","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jmb.2025.169384_b0345","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2009.27.5644","article-title":"Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy","volume":"29","author":"Press","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.jmb.2025.169384_b0350","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/bjc.1996.286","article-title":"Differential expression of the topoisomerase II alpha and beta genes in human breast cancers","volume":"73","author":"Sandri","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jmb.2025.169384_b0355","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.220232","article-title":"DNA fragility at the KMT2A\/MLL locus: insights from old and new technologies","volume":"13","author":"Cowell","year":"2023","journal-title":"Open Biol."},{"key":"10.1016\/j.jmb.2025.169384_b0360","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1530\/ERC-12-0403","article-title":"TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma","volume":"20","author":"Jain","year":"2013","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.jmb.2025.169384_b0365","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s12885-018-4170-7","article-title":"The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer","volume":"18","author":"An","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jmb.2025.169384_b0370","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.ajpath.2010.12.042","article-title":"Assessment of topoisomerase II \u03b1 status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization","volume":"178","author":"Romero","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jmb.2025.169384_b0375","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1007\/s10528-023-10544-0","article-title":"Potential signature therapeutic biomarkers TOP2A, MAD2L1, and CDK1 in colorectal cancer: a systems biomedicine-based approach","volume":"62","author":"Priyamvada","year":"2024","journal-title":"Biochem. Genet."},{"key":"10.1016\/j.jmb.2025.169384_b0380","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1097\/CM9.0000000000001075","article-title":"Topoisomerase II alpha promotes gallbladder cancer proliferation and metastasis through activating phosphatidylinositol 3-kinase\/protein kinase B\/mammalian target of rapamycin signaling pathway","volume":"133","author":"Lyu","year":"2020","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.jmb.2025.169384_b0385","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12038-022-00322-2","article-title":"E2F1-mediated up-regulation of TOP2A promotes viability, migration, and invasion, and inhibits apoptosis of gastric cancer cells","volume":"47","author":"Chen","year":"2022","journal-title":"J. Biosci."},{"key":"10.1016\/j.jmb.2025.169384_b0390","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.humpath.2006.05.008","article-title":"Topoisomerase II\u03b1 gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study","volume":"37","author":"Kanta","year":"2006","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.jmb.2025.169384_b0395","doi-asserted-by":"crossref","first-page":"57574","DOI":"10.18632\/oncotarget.15895","article-title":"TOP2A, GGH, and PECAM1 are associated with hematogenous, lymph node, and peritoneal recurrence in stage II\/III gastric cancer patients enrolled in the ACTS-GC study","volume":"8","author":"Terashima","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmb.2025.169384_b0400","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/ijc.34631","article-title":"Targeted sequencing of cancer\u2010related genes reveals a recurrent TOP2A variant which affects DNA binding and coincides with global transcriptional changes in glioblastoma","volume":"153","author":"Gielniewski","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jmb.2025.169384_b0405","first-page":"1228","article-title":"Over-expression of TOP2A as a prognostic biomarker in patients with glioma","volume":"11","author":"Zhou","year":"2018","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.jmb.2025.169384_b0410","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3892\/ol.2020.12095","article-title":"High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis","volume":"20","author":"Cai","year":"2020","journal-title":"Oncol. Letters"},{"key":"10.1016\/j.jmb.2025.169384_b0415","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12935-019-0956-1","article-title":"Prognostic significance of TOP2A in non-small cell lung cancer revealed by bioinformatic analysis","volume":"19","author":"Ma","year":"2019","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.jmb.2025.169384_b0420","doi-asserted-by":"crossref","first-page":"12228","DOI":"10.1038\/s41598-024-63055-2","article-title":"Expression and potential molecular mechanism of TOP2A in metastasis of non-small cell lung cancer","volume":"14","author":"Wu","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jmb.2025.169384_b0425","doi-asserted-by":"crossref","first-page":"58","DOI":"10.26502\/droh.0076","article-title":"Effects of topoisomerase II alpha inhibition on oral cancer cell metabolism and cancer stem cell function","volume":"7","author":"Kanagasabai","year":"2024","journal-title":"Dent. Res. Oral Health"},{"key":"10.1016\/j.jmb.2025.169384_b0430","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.3390\/curroncol31120594","article-title":"Targeting TOP2A in ovarian cancer: biological and clinical implications","volume":"31","author":"Borella","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.jmb.2025.169384_b0435","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.7150\/jca.42736","article-title":"TOP2A promotes tumorigenesis of high-grade serous ovarian cancer by regulating the TGF-\u03b2\/Smad pathway","volume":"11","author":"Gao","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.jmb.2025.169384_b0440","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2024.2325126","article-title":"TOP2A modulates signaling via the AKT\/mTOR pathway to promote ovarian cancer cell proliferation","volume":"25","author":"Zhang","year":"2024","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jmb.2025.169384_b0445","first-page":"197","article-title":"TOP2A induces malignant character of pancreatic cancer through activating \u03b2-catenin signaling pathway","volume":"2018","author":"Pei","year":"1864","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.jmb.2025.169384_b0450","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1007\/s10620-017-4718-4","article-title":"Overexpression of topoisomerase 2-alpha confers a poor prognosis in pancreatic adenocarcinoma identified by co-expression analysis","volume":"62","author":"Zhou","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.jmb.2025.169384_b0455","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1479-5876-11-36","article-title":"Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer","volume":"11","author":"de Resende","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jmb.2025.169384_b0460","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.3390\/cancers13194877","article-title":"Expression patterns of TOP2A and SIRT1 are predictive of survival in patients with high-risk soft tissue sarcomas treated with a neoadjuvant anthracycline-based chemotherapy","volume":"13","author":"Berclaz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jmb.2025.169384_b0465","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1245\/s10434-011-2184-3","article-title":"Prognostication of soft tissue sarcomas based on chromosome 17q gene and protein status: evaluation of TOP2A, HER-2\/neu, and survivin","volume":"19","author":"da Cunha","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.jmb.2025.169384_b0470","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/gcc.22124","article-title":"The role of topoisomerase II beta on breakage and proximity of RUNX1 to partner alleles RUNX1T1 and EVI1","volume":"53","author":"Smith","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jmb.2025.169384_b0475","doi-asserted-by":"crossref","first-page":"8229","DOI":"10.3748\/wjg.v20.i25.8229","article-title":"Inhibition of Girdin enhances chemosensitivity of colorectal cancer cells to oxaliplatin","volume":"20","author":"Zhang","year":"2014","journal-title":"World J. Gastroenterol.: WJG"},{"key":"10.1016\/j.jmb.2025.169384_b0480","doi-asserted-by":"crossref","first-page":"5987","DOI":"10.1007\/s12035-022-02949-6","article-title":"TOP2B is required to maintain the adrenergic neural phenotype and for ATRA-induced differentiation of SH-SY5Y neuroblastoma cells","volume":"59","author":"Khazeem","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jmb.2025.169384_b0485","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1038\/s41467-021-26640-x","article-title":"The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma","volume":"12","author":"Pan","year":"2021","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2025.169384_b0490","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1538-7445.AM2022-680","article-title":"Abstract 680: topoisomerase 2 beta facilitates chromatin reorganization during androgen receptor induced transcription and contributes to chromoplexy in prostate cancer","volume":"82","author":"Pham","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169384_b0495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174515","article-title":"Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan\u2013Meier plotter","volume":"12","author":"Hou","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jmb.2025.169384_b0500","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.3390\/ijms25115674","article-title":"Bioinformatic analysis of topoisomerase II\u03b1 reveals interdomain interdependencies and critical C-terminal domain residues","volume":"25","author":"Endsley","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jmb.2025.169384_b0505","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1083\/jcb.200112023","article-title":"Dynamics of human DNA topoisomerases II\u03b1 and II\u03b2 in living cells","volume":"157","author":"Christensen","year":"2002","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jmb.2025.169384_b0510","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrc2608","article-title":"DNA topoisomerase II and its growing repertoire of biological functions","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nature Rev. Cancer"},{"key":"10.1016\/j.jmb.2025.169384_b0515","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/20.21.5587","article-title":"Isolation of cDNA clones encoding the \u03b2 isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24","author":"Jenkins","year":"1992","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169384_b0520","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkm102","article-title":"C-Terminal regions of topoisomerase II\u03b1 and II\u03b2 determine isoform-specific functioning of the enzymes in vivo","author":"Linka","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169384_b0525","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/386414a0","article-title":"An atypical topoisomerase II from Archaea with implications for meiotic recombination","volume":"386","author":"Bergerat","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169384_b0530","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0968-0004(99)01503-0","article-title":"GHKL, an emergent ATPase\/kinase superfamily","volume":"25","author":"Dutta","year":"2000","journal-title":"Trends Biochem. Sci"},{"key":"10.1016\/j.jmb.2025.169384_b0535","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1832879100","article-title":"Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187","author":"Classen","year":"2003","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169384_b0540","doi-asserted-by":"crossref","first-page":"37041","DOI":"10.1074\/jbc.M506520200","article-title":"Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase","volume":"280","author":"Wei","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2025.169384_b0545","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1038\/s41467-021-23136-6","article-title":"Structural basis for allosteric regulation of human topoisomerase II\u03b1","volume":"12","author":"Vanden Broeck","year":"2021","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2025.169384_b0550","article-title":"Structural insights into the gating of DNA passage by the topoisomerase II DNA-gate","author":"Chen","year":"2018","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2025.169384_b0555","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.275.17.13041","article-title":"Communication between the ATPase and cleavage\/religation domains of human topoisomerase II\u03b1","author":"Bjergbaek","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2025.169384_b0560","doi-asserted-by":"crossref","DOI":"10.1146\/annurev.biophys.33.110502.140357","article-title":"Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases","author":"Corbett","year":"2004","journal-title":"Annu. Rev. Biophys. Biomol. Struct."},{"key":"10.1016\/j.jmb.2025.169384_b0565","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1093\/nar\/26.18.4205","article-title":"Toprim\u2013a conserved catalytic domain in type IA and II topoisomerases, DnaG-type primases, OLD family nucleases and RecR proteins","volume":"26","author":"Aravind","year":"1998","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169384_b0570","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0022-2836(02)00049-9","article-title":"The role of GyrB in the DNA cleavage-religation reaction of DNA gyrase: a proposed two metal-ion mechanism","volume":"318","author":"Noble","year":"2002","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jmb.2025.169384_b0575","doi-asserted-by":"crossref","first-page":"8940","DOI":"10.1021\/bi900875c","article-title":"Metal ion interactions in the DNA cleavage\/ligation active site of human topoisomerase IIalpha","volume":"48","author":"Deweese","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.jmb.2025.169384_b0580","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/bi8023256","article-title":"Use of divalent metal ions in the DNA cleavage reaction of human type II topoisomerases","volume":"48","author":"Deweese","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.jmb.2025.169384_b0585","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nature08974","article-title":"A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases","volume":"465","author":"Schmidt","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169384_b0590","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/bi991328b","article-title":"Mutagenesis of E477 or K505 in the B\u2032 domain of human topoisomerase II beta increases the requirement for magnesium ions during strand passage","volume":"39","author":"West","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.jmb.2025.169384_b0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2012.07.014","article-title":"The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage","author":"Wendorff","year":"2012","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jmb.2025.169384_b0600","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/379225a0","article-title":"Structure and mechanism of DNA topoisomerase II","volume":"379","author":"Berger","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169384_b0605","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tibs.2013.04.006","article-title":"From keys to bulldozers: expanding roles for winged helix domains in nucleic-acid-binding proteins","volume":"38","author":"Harami","year":"2013","journal-title":"Trends Biochem. Sci"},{"key":"10.1016\/j.jmb.2025.169384_b0610","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0092-8674(94)90222-4","article-title":"DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism","volume":"77","author":"Roca","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2025.169384_b0615","doi-asserted-by":"crossref","first-page":"13502","DOI":"10.1021\/bi9912488","article-title":"Probing the two-gate mechanism of DNA gyrase using cysteine cross-linking","volume":"38","author":"Williams","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.jmb.2025.169384_b0620","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf330","article-title":"Different propensities for gate opening in gyrases and topoisomerase IV","volume":"53","author":"Willing","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169384_b0625","doi-asserted-by":"crossref","DOI":"10.1006\/excr.1997.3805","article-title":"Bipartite nuclear localization signals in the C terminus of human topoisomerase II\u03b1","author":"Mirski","year":"1997","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jmb.2025.169384_b0630","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1083\/jcb.201303045","article-title":"A novel chromatin tether domain controls topoisomerase II\u03b1 dynamics and mitotic chromosome formation","volume":"203","author":"Lane","year":"2013","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jmb.2025.169384_b0635","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S0033583598003424","article-title":"Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine","volume":"31","author":"Wang","year":"1998","journal-title":"Q. Rev. Biophys."},{"key":"10.1016\/j.jmb.2025.169384_b0640","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/nature06396","article-title":"Structural basis for gate-DNA recognition and bending by type IIA topoisomerases","volume":"450","author":"Dong","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169384_b0645","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jmb.2008.11.056","article-title":"How do type II topoisomerases use ATP hydrolysis to simplify DNA topology beyond equilibrium? Investigating the relaxation reaction of nonsupercoiling type II topoisomerases","volume":"385","author":"Stuchinskaya","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jmb.2025.169384_b0650","doi-asserted-by":"crossref","first-page":"8163","DOI":"10.1093\/nar\/gkz579","article-title":"A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents","volume":"47","author":"Blower","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169384_b0655","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2302064120","article-title":"Naturally mutagenic sequence diversity in a human type II topoisomerase","volume":"120","author":"Bandak","year":"2023","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169384_b0660","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.7150\/jca.41415","article-title":"TOP2A promotes lung adenocarcinoma cells\u2019 malignant progression and predicts poor prognosis in lung adenocarcinoma","volume":"11","author":"Kou","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.jmb.2025.169384_b0665","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.jmb.2025.169384_b0670","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal","volume":"83","author":"De Bruijn","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169384_b0675","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The cancer genome atlas pan-cancer analysis project","volume":"45","author":"Weinstein","year":"2013","journal-title":"Nature Genet."},{"key":"10.1016\/j.jmb.2025.169384_b0680","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jmb.2025.169384_b0685","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1002\/humu.24491","article-title":"SPiP: splicing prediction pipeline, a machine learning tool for massive detection of exonic and intronic variant effects on mRNA splicing","volume":"43","author":"Leman","year":"2022","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.jmb.2025.169384_b0690","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169384_b0695","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/ng.2892","article-title":"A general framework for estimating the relative pathogenicity of human genetic variants","volume":"46","author":"Kircher","year":"2014","journal-title":"Nature Genet."},{"key":"10.1016\/j.jmb.2025.169384_b0700","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/humu.20334","article-title":"TGFBI gene mutations in corneal dystrophies","volume":"27","author":"Kannabiran","year":"2006","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.jmb.2025.169384_b0705","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","article-title":"A method and server for predicting damaging missense mutations","volume":"7","author":"Adzhubei","year":"2010","journal-title":"Nature Methods"},{"key":"10.1016\/j.jmb.2025.169384_b0710","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1093\/nar\/gkg509","article-title":"SIFT: predicting amino acid changes that affect protein function","volume":"31","author":"Ng","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169384_b0715","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nmeth.2890","article-title":"MutationTaster2: mutation prediction for the deep-sequencing age","volume":"11","author":"Schwarz","year":"2014","journal-title":"Nature Methods"},{"key":"10.1016\/j.jmb.2025.169384_b0720","doi-asserted-by":"crossref","DOI":"10.1126\/science.adg7492","article-title":"Accurate proteome-wide missense variant effect prediction with AlphaMissense","volume":"381","author":"Cheng","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169384_b0725","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2114024119","article-title":"Recurrent mutations in topoisomerase II\u03b1 cause a previously undescribed mutator phenotype in human cancers","author":"Boot","year":"2022","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169384_b0730","article-title":"Oncogenetic function and prognostic value of DNA topoisomerase II alpha in human malignances: a pan-cancer analysis","author":"Zhao","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.jmb.2025.169384_b0735","doi-asserted-by":"crossref","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","article-title":"COSMIC: a curated database of somatic variants and clinical data for cancer","volume":"52","author":"Sondka","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169384_b0740","doi-asserted-by":"crossref","DOI":"10.1006\/excr.1999.4587","article-title":"Sequence determinants of nuclear localization in the \u03b1 and \u03b2 isoforms of human topoisomerase II","author":"Mirski","year":"1999","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jmb.2025.169384_b0745","article-title":"Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase II\u03b1 in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization","author":"Wessel","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169384_b0750","doi-asserted-by":"crossref","DOI":"10.1021\/bi962400y","article-title":"Two COOH-terminal truncated cytoplasmic forms of topoisomerase II\u03b1 in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing","author":"Yu","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.jmb.2025.169384_b0755","first-page":"2129","article-title":"Cytoplasmic localization of a mutant Mr 160,000 topoisomerase II\u03b1 is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line","volume":"55","author":"Mirski","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169384_b0760","first-page":"10","article-title":"Mutagenesis of intrinsically disordered domain impacts topoisomerase II \u03b1 catalytic activity","volume":"26","author":"Chang","year":"2025","journal-title":"Int. J. Mol."},{"key":"10.1016\/j.jmb.2025.169384_b0765","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1006\/excr.1998.4150","article-title":"Nuclear distribution of human DNA topoisomerase II\u03b2: a nuclear targeting signal resides in the 116-residue C-terminal tail","volume":"243","author":"Cowell","year":"1998","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jmb.2025.169384_b0770","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/cncr.34350","article-title":"Real\u2010life data on treatment and outcomes in advanced ovarian cancer: an observational, multinational cohort study (RESPONSE trial)","author":"Marth","year":"2022","journal-title":"Cancer 128"},{"key":"10.1016\/j.jmb.2025.169384_b0775","doi-asserted-by":"crossref","first-page":"9788","DOI":"10.1093\/nar\/gkae657","article-title":"Structural insights into the assembly of type IIA topoisomerase DNA cleavage-religation center","volume":"52","author":"Liu","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169384_b0780","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019101863","article-title":"Histone H2A phosphorylation recruits topoisomerase II \u03b1 to centromeres to safeguard genomic stability","author":"Zhang","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.jmb.2025.169384_b0785","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/pmic.200700896","article-title":"Phosphoproteome analysis of the human Chang liver cells using SCX and a complementary mass spectrometric strategy","volume":"8","author":"Sui","year":"2008","journal-title":"Proteomics"},{"key":"10.1016\/j.jmb.2025.169384_b0790","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.adl5899","article-title":"Structural basis of DNA crossover capture by Escherichia coli DNA gyrase","volume":"384","author":"Vayssi\u00e8res","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169384_b0795","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032532","article-title":"A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents","volume":"24","author":"Okoro","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jmb.2025.169384_b0800","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1126\/science.1204117","article-title":"Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide","volume":"333","author":"Wu","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169384_b0805","doi-asserted-by":"crossref","first-page":"25947","DOI":"10.1074\/jbc.M312314200","article-title":"A mutation in human topoisomerase II \u03b1 whose expression is lethal in DNA repair-deficient yeast cells","volume":"279","author":"Walker","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2025.169384_b0810","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/nar\/gkh339","article-title":"The \u03b14 residues of human DNA topoisomerase II\u03b1 function in enzymatic activity and anticancer drug sensitivity","volume":"32","author":"Suda","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169384_b0815","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.65184","article-title":"Transcription-associated topoisomerase 2\u03b1 (Top2a) activity is a major effector of cytotoxicity induced by g-quadruplex ligands","volume":"10","author":"Bossaert","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.jmb.2025.169384_b0820","doi-asserted-by":"crossref","DOI":"10.3389\/fphy.2024.1358406","article-title":"Insights into the structure\u2013function relationship of missense mutations in the human TOP2A protein in ovarian cancer","volume":"12","author":"Kavitha","year":"2024","journal-title":"Front. Phys."},{"key":"10.1016\/j.jmb.2025.169384_b0825","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1470-2045(15)00201-6","article-title":"Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study","volume":"16","author":"Ravandi","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jmb.2025.169384_b0830","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010186","article-title":"Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II","volume":"5","author":"Hawtin","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jmb.2025.169384_b0835","doi-asserted-by":"crossref","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169384_b0840","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s42004-023-00920-7","article-title":"A mutation-induced drug resistance database (MdrDB)","volume":"6","author":"Yang","year":"2023","journal-title":"Commun. Chem."},{"key":"10.1016\/j.jmb.2025.169384_b0845","doi-asserted-by":"crossref","first-page":"8861","DOI":"10.1021\/bi00424a026","article-title":"Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26","volume":"27","author":"Danks","year":"1988","journal-title":"Biochemistry"},{"key":"10.1016\/j.jmb.2025.169384_b0850","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1054\/bjoc.1999.0947","article-title":"Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance","volume":"82","author":"Lage","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jmb.2025.169384_b0855","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4062\/biomolther.2016.168","article-title":"Proposal of dual inhibitor targeting ATPase domains of topoisomerase II and heat shock protein 90","volume":"24","author":"Jun","year":"2016","journal-title":"Biomol. Ther."},{"key":"10.1016\/j.jmb.2025.169384_b0860","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1124\/mol.105.015933","article-title":"Mutation P732L in human DNA topoisomerase II\u03b2 abolishes DNA cleavage in the presence of calcium and confers drug resistance","volume":"69","author":"Leontiou","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jmb.2025.169384_b0865","first-page":"1373","article-title":"Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells","volume":"53","author":"Danks","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169384_b0870","doi-asserted-by":"crossref","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","author":"Nitiss","year":"2009","journal-title":"Nature Rev. Cancer"},{"key":"10.1016\/j.jmb.2025.169384_b0875","first-page":"1","article-title":"Advances in research on malignant tumors and targeted agents for TOP2A (Review)","volume":"31","author":"Zhou","year":"2025","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jmb.2025.169384_b0880","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/1568011054222364","article-title":"Etoposide, topoisomerase II and cancer","volume":"5","author":"Baldwin","year":"2005","journal-title":"Curr. Med. Chem.-Anti-Cancer Agents"},{"key":"10.1016\/j.jmb.2025.169384_b0885","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1124\/mol.106.032953","article-title":"Differential selection of acridine resistance mutations in human DNA topoisomerase IIbeta is dependent on the acridine structure","volume":"71","author":"Leontiou","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jmb.2025.169384_b0890","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/nar\/gkl057","article-title":"mAMSA resistant human topoisomerase II\u03b2 mutation G465D has reduced ATP hydrolysis activity","volume":"34","author":"Gilroy","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169384_b0895","first-page":"2943","article-title":"Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide","volume":"54","author":"Liu","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169384_b0900","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1038\/s41467-025-60167-9","article-title":"Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection","volume":"16","author":"Kube\u0161","year":"2025","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2025.169384_b0905","doi-asserted-by":"crossref","first-page":"26876","DOI":"10.1073\/pnas.2008721117","article-title":"Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast","volume":"117","author":"Stantial","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169384_b0910","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3390\/sym14071309","article-title":"Structural and biochemical basis of etoposide-resistant mutations in topoisomerase II\u03b1","volume":"14","author":"Gibson","year":"2022","journal-title":"Symmetry"},{"key":"10.1016\/j.jmb.2025.169384_b0915","doi-asserted-by":"crossref","first-page":"8288","DOI":"10.1073\/pnas.93.16.8288","article-title":"Active heterodimers are formed from human DNA topoisomerase II alpha and II beta isoforms","volume":"93","author":"Biersack","year":"1996","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169384_b0920","doi-asserted-by":"crossref","first-page":"16645","DOI":"10.1021\/bi981391l","article-title":"Characterization of DNA topoisomerase II\u03b1\/\u03b2 heterodimers in HeLa cells","volume":"37","author":"Gromova","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.jmb.2025.169384_b0925","unstructured":"National Comprehensive Cancer Network, Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer, National Comprehensive Cancer Network, 2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1453 (accessed July 7, 2025)."},{"key":"10.1016\/j.jmb.2025.169384_b0930","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial","volume":"29","author":"Pignata","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.jmb.2025.169384_b0935","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.jmb.2025.169384_b0940","series-title":"Pegylated Liposomal Doxorubicin for First-line Treatment of Epithelial Ovarian Cancer","year":"2013"},{"key":"10.1016\/j.jmb.2025.169384_b0945","doi-asserted-by":"crossref","first-page":"viii332","DOI":"10.1093\/annonc\/mdy285.142","article-title":"Carboplatin\/pegylated liposomal doxorubicin\/bevacizumab (CD-BEV) vs. carboplatin\/gemcitabine\/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: a prospective randomized phase III ENGOT\/GCIG-Intergroup study (AGO study group)","volume":"29","author":"Pfisterer","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jmb.2025.169384_b0950","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","article-title":"Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study","volume":"16","author":"Rose","year":"1998","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.jmb.2025.169384_b0955","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.jmb.2025.169384_b0960","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2147\/CMAR.S15558","article-title":"Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer","volume":"3","author":"Markman","year":"2011","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.jmb.2025.169384_b0965","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.jmb.2025.169384_b0970","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.jmb.2025.169384_b0975","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.jmb.2025.169384_b0980","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e17575","article-title":"Clinical features of long-term survivors with advanced high-grade serous ovarian cancer","volume":"41","author":"Barretina-Ginesta","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jmb.2025.169384_b0985","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.prp.2014.06.017","article-title":"Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer","volume":"210","author":"Almeida","year":"2014","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.jmb.2025.169384_b0990","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1158\/1078-0432.CCR-09-2471","article-title":"ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction","volume":"16","author":"Brase","year":"2010","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.jmb.2025.169384_b0995","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(11)70231-5","article-title":"HER2\/TOP2A Meta-analysis Study Group, HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data","volume":"12","author":"Di Leo","year":"2011","journal-title":"Lancet Oncol."},{"issue":"83","key":"10.1016\/j.jmb.2025.169384_b1000","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2017.06.019","article-title":"Topoisomerase expression and amplification in solid tumours: analysis of 24,262 patients","volume":"1990","author":"Heestand","year":"2017","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.jmb.2025.169384_b1005","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/jnci\/djp067","article-title":"Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy","volume":"101","author":"O\u2019Malley","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jmb.2025.169384_b1010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006891","article-title":"Natural variation in a single amino acid substitution underlies physiological responses to topoisomerase II poisons","volume":"13","author":"Zdraljevic","year":"2017","journal-title":"PLoS Genet."}],"container-title":["Journal of Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022283625004504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022283625004504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T07:59:37Z","timestamp":1782028777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022283625004504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":202,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0022283625004504"],"URL":"https:\/\/doi.org\/10.1016\/j.jmb.2025.169384","relation":{},"ISSN":["0022-2836"],"issn-type":[{"value":"0022-2836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA Topoisomerase II Mutations in Cancer: Structural Impact and Drug Response in High-grade Serous Ovarian Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmb.2025.169384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"169384"}}